Get ready to mark your calendars because the much anticipated third quarter financial results of Cytokinetics Incorporated (NASDAQ: CYTK) are set to be unveiled on Wednesday 6th November 2024. Investors and market watchers will have the chance to dive into the company's financial performance as the announcement is scheduled after market close.
It appears that the enterprise is on the verge of revealing their estimated $1.25 loss per share for the quarter, as well as their total revenue of $1.19 million for this specific period, according to financial experts on Wall Street.
The earnings report for the corresponding quarter in the previous year showcased a per-share loss of $1.35. This considerable sum was attributed to the company's total revenue, which reached an impressive $0.38 million during that specific quarter.
Wall Street analysts have unveiled their forecasts for the company's yearly performance, estimating a total revenue of $7.34 million. Additionally, they expect the company to reach loss of $5.18 per share for the fiscal year.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-1.31 | +2.2% | 0.25 M | -71.3% |
| Q1 2024 | $-1.33 | +3.6% | 0.84 M | -81.9% |
| Q4 2023 | $-1.38 | +4.8% | 1.67 M | -14.6% |
| Q3 2023 | $-1.35 | +11.2% | 0.38 M | -85.0% |
| Q2 2023 | $-1.34 | -482.6% | 0.87 M | -99.0% |
| *Growth on year-over-year basis | ||||
In addition, The firm will review the third quarter financial results on 6th November 2024 at 04:30 PM eastern time, in a conference call with public.
Cytokinetics Incorporated (CYTK) shares experienced a range of $51.07 to $52.36 on a day volume of 857.90 thousand shares. The stock closed Friday's regular trading session at $51.82, reflecting a 1.61 percent rise.
